Clinical laboratory indices in the treatment of acromegaly

Clinica Chimica Acta

Volumn 412, Issue 5-6, 2011, Pages 403-409

  Clemmons, David R ^a  

^a UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

Author keywords

Acromegaly; Growth hormone; IGF I

Indexed keywords

GLUCOSE; GROWTH HORMONE; HEMOGLOBIN A1C; SOMATOMEDIN C;

ACROMEGALY; ALGORITHM; BODY MASS; DISEASE ACTIVITY; HORMONE BLOOD LEVEL; HORMONE DETERMINATION; HUMAN; MORTALITY; ORAL GLUCOSE TOLERANCE TEST; OUTCOME ASSESSMENT; PATHOPHYSIOLOGY; PRIORITY JOURNAL; REPRODUCIBILITY; REVIEW;

ACROMEGALY; CLINICAL LABORATORY TECHNIQUES; HUMAN GROWTH HORMONE; HUMANS; INSULIN-LIKE GROWTH FACTOR I; SENSITIVITY AND SPECIFICITY;

EID: 78650892585     PISSN: 00098981     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cca.2010.11.008     Document Type: Review

References (72)

1. Melmed S., Braunstein G.D., Horvath E., Ezrin C., Kovacs K. Pathophysiology of acromegaly. Endocr Rev 1983, 4:271-290.
2. Sano T., Asa S.L., Kovacs K. Growth hormone-releasing hormone producing tumors: clinical, biochemical, and morphological manifestations. Endocr Rev 1988, 9:357-373.
3. Melmed S. Acromegaly. New Engl J Med 2006, 355:2558-2573.
4. Nabarro J.D.N. Acromegaly. Clin Endocrinol 1987, 26:481-512.
5. Tolis G., Angelopoulos N.G., Katounda E., et al. Medical treatment of acromegaly: comorbidities and their reversibility by somatostatin analogs. Neuroendocrinology 2006, 83:249-257.
6. Holdaway I.M., Rajasoorya R.C., Gamble G.D. Factors influencing mortality in acromegaly. J Clin Endocrinol Metab 2004, 89:667-674.
7. Abosch A., Tyrrell J.B., Lamborn K.R., Hannegan L.T., Applebury C.B., Wilson C.B. Transsphenoidal microsurgery for growth hormone-secreting pituitary adenomas: initial outcomes and long-term results. J Clin Endocrinol Metab 1998, 83:3411-3418.
8. Goldenberg N., Barkan A. Factors regulating growth hormone secretion in humans. Endocrinol Metab Clin North Am 2007, 36:37-55.
9. Mercado M., et al. Clinical-biochemical correlations in acromegaly at diagnosis and the real prevalence of biochemically discordant disease. Horm Res 2004, 62:293-299.
10. Clemmons D.R. Value of insulin-like growth factor system markers in the assessment of growth hormone status. Endocrinol Metab Clin North Am 2007, 36:109-129.
11. Barkan A.L. Biochemical markers of acromegaly: GH vs IGF-I. Growth Horm &IGF Res 2004, 14:S97-S100.
12. Faje A.T., Barkan A.L. Basal, but not pulsatile, growth hormone secretion determines the ambient circulating levels of insulin-like growth factor-I. J Clin Endocrinol Metab 2010, 95:2486-2491.
13. Clemmons D.R., Van Wyk J.J., Ridgway E.C., Kliman B., Kjelberg R.N., Underwood L.E. Evaluation of acromegaly by radioimmunoassay of somatomedin-C. N Engl J Med 1979, 201:1138-1142.
14. Giustina A., Chanson P., Bronstein M.D., et al. A consensus on criteria for cure of acromegaly. J Clin Endocrinol Metab 2010, 95:3141-3148.
15. Trainer P.J. Editorial: acromegaly-consensus, what consensus?. J Clin Endocrinol Metab 2002, 87:3534-3536.
16. Sata K., Ho K. Growth hormone measurements in the diagnosis and monitoring of acromegaly. Pituitary 2007, 10:165-172.
17. Strasburger C.J. Biochemical assessment and long-term monitoring in patients with acromegaly: statement from a joint consensus conference of The Growth Hormone Research Society and The Pituitary Society. J Clin Endocrinol Metab 2004, 89:3099-4002.
18. Sherlock M., Aragon A.A., Reulen R.C., et al. Monitoring disease activity using GH and IGF-I in the follow up of 501 patients with acromegaly. Clin Endocrinol 2009, 71:74-81.
19. Jayasena C.N., Wujanto C., Donaldson M., Todd J.F., Meeran K. Measurement of basal growth hormone (GH) is a useful test of disease activity in treated acromegalic patients. Clin Endocrinol 2008, 68:36-41.
20. Feelders R.A., Bidlingmaier M., Strasburger C.J., et al. Postoperative evaluation of patients with acromegaly: clinical significance and timing of oral glucose tolerance testing and measurement of (free) insulin-like growth factor I, acid-labile subunit, and growth hormone-binding protein levels. J Clin Endocrinol Metab 2005, 90:6480-6489.
21. Freda P.U., Nuruzzaman A.T., Reyes C.M., Sundeen R.E., Post K.D. Significance of "abnormal" nadir growth hormone levels after oral glucose in postoperative patients with acromegaly in remission with normal insulin-like growth factor-I levels. J Clin Endocrinol Metab 2004, 89:495-500.
22. Carmichael J.D., Bonert V.S., Mirocha J.M., Melmed S. The utility of oral glucose tolerance testing for diagnosis and assessment of treatment outcomes in 166 patients with acromegaly. J Clin Endocrinol Metab 2009, 94:523-527.
23. Karavitaki N., Fernandez A., Fazal-Sanderson V., Wass J.A. The value of the oral glucose tolerance test, random serum growth hormone and mean growth hormone levels in assessing the postoperative outcome of patients with acromegaly. Clin Endocrinol 2009, 840-846.
24. Ronchi C.L., Arosio M., Rizzo E., Lania A.G., Beck-Peccoz P., Spada A. Adequacy of current postglucose GH nadir limit (<1microg/l) to define long-lasting remission of acromegalic disease. Clin Endocrinol 2007, 66:538-542.
25. Munzer T., Rosen C.J., Harman S.M., Pabst K.M., St Clair C., Sorkin J.D., et al. Effects of GH and/or sex steroids on circulating IGF-I and IGFBPs in healthy, aged women and men. Am J Physiol Endocrinol Metab 2006, 290:E1006-E1013.
26. Meinhardt U.J., Ho K. Modulation of growth hormone action by sex steroids. Clin Endocrinol 2006, 63:413-422.
27. Ho K.Y., Weissberger A.J. Characterization of 24-hour growth hormone secretion in acromegaly: implications for diagnosis and therapy. Clin Endocrinol 1994, 41:75-83.
28. Peacey S.R., Toogood A.A., Veldhuis J.D., Thorner M.O., Shalet M. The relationship between 24-hour growth hormone secretion and insulin-like growth factor I in patients with successfully treated acromegaly: impact of surgery or radiotherapy. J Clin Endocrinol Metab 2001, 86:259-266.
29. Tanimoto K., Hizuka N., Fukuda I., Takano K., Hanafusa T. The influence of age on the GH-IGF1 axis in patients with acromegaly. Eur J Endocrinol 2008, 159:375-379.
30. Coloa A., Pivonello R., Cavallo L.M., et al. Age changes the diagnostic accuracy of mean profile and nadir growth hormone levels after oral glucose in postoperative patients with acromegaly. Clin Endocrinol 2006, 65:250-256.
31. Kreitschmann-Andermahr I., Suarez P., Jennings R., Evers N., Brabant G. GH/IGF-I regulation in obesity-mechanisms and practical consequences in children and adults. Horm Res Paediatr 2010, 73:153-160.
32. Brabant G., Wallaschofski H. Normal levels of serum IGF-I: determinants and validity of current reference ranges. Pituitary 2007, 10:129-133.
33. Meinhardt U.J., Ho K.K. Regulation of growth hormone action by gonadal steroids. Endocrinol Metab Clin North Am 2007, 36:57-73.
34. Leung K.C., Johannsson G., Leong G.M., Ho K.K. Estrogen regulation of growth hormone action. Endocr Rev 2004, 25:693-721.
35. Puder J.J., Nilavar S., Post K.D., Freda P.U. Relationship between disease-related mobidity and biochemical markers of activity in patients with acromegaly. J Clin Endocrinol Metab 2005, 90:1972-1978.
36. Dimaraki E.V., Jaffe C.A., DeMott-Friberg R., Chandler W.F., Barkan A.L. Acromegaly with apparently normal GH secretion: implications for diagnosis and follow-up. J Clin Endocrinol Metab 2002, 87:3537-3542.
37. th minute postglucose value with spontaneous GH secretion and with the IGF system. Clin Endocrinol 2004, 61:138-144.
38. Grinspoon S., Clemmons D., Swearingen B., Klibanski A. Serum insulin-like growth factor-binding protein-3 levels in the diagnosis of acromegaly. J Clin Endocrinol Metab 1995, 80:927-932.
39. Gullu S., Keles H., Delibasi T., Tonyukuk V., Kamel N., Erdogan G. Remission criteria for the follow up of patients with acromegaly. Eur J Endocrinol 2004, 150:465-471.
40. Elias P.C., Lugao H.B., Pereira M.C., Machado H.R., Castro M., Moreira A.C. Discordant nadir GH after oral glucose and IGF-I levels on treated acromegaly: refining the biochemical markers of mild disease activity. Horm Metab Res 2010, 42:50-55.
41. Alexopoulou O., Bex M., Abs R., T'Sjoen G., Velkeniers B., Maiter D. Divergence between growth hormone and insulin-like growth factor-I concentrations in the follow-up of acromegaly. J Clin Endocrinol Metab 2008, 93:1324-1330.
42. Serri O., Bauregard C., Hardy J. Long-term biochemical status and disease-related morbidity in 53 postoperative patients with acromegaly. J Clin Endocrinol Metab 2004, 89:658-661.
43. Espinosa-de-los-Monteros A.L., Mercado M., Sosa E. Changing patterns of insulin-like growth factor-I and glucose suppressed growth hormone levels after pituitary surgery in patients with acromegaly. J Neurosurg 2002, 97:287-292.
44. Machado E.O., Taboada G.F., Neto L.V. Prevalence of discordant GH and IGF-I levels in acromegalics at diagnosis, after surgical treatment and during treatment with octreotide LAR. Growth Horm IGF Res 2008, 18:389-393.
45. Bates A.S., Evans A.J., Jones P., Clayton R.N. Assessment of GH status in acromegaly using serum growth hormone, serum insulin-like growth factor-1 and urinary growth hormone excretion. Clin Endocrinol 1995, 42:417-423.
46. Kaltsas G.A., Isidori A.M., Florakis D., et al. Predictors of the outcome of surgical treatment in acromegaly and the value of the mean growth hormone curve in assessing postoperative disease activity. J Clin Endocrinol Metab 2001, 86:1645-1652.
47. Wass J.A. Growth hormone, insulin-like growth factor-I and its binding proteins in the follow up of acromegaly. J Endocrinol 1997, 155:S17-S19.
48. Costa A.C., Rossi A., Martinelli C.E., Machado H.R., Moreira A.C. Assessment of disease activity in treated acromegalic patients using a sensitive GH assay: should we achieve strict normal GH levels for a biochemical cure?. J Clin Endocrinol Metab 2002, 87:3142-3147.
49. Ayuk J., Clayton R.N., Holder G., Sheppard M.C., Stewart P.M., Bates A.S. Growth hormone and pituitary radiotherapy, but not serum insulin-like growth factor-I concentrations predict excess mortality in patients with acromegaly. J Clin Endocrinol Metab 2004, 89:1613-1617.
50. Vierhapper H., Heinze G., Gessi A., Exner M., Bieglmayr C. Use of the oral glucose tolerance test to define remission in acromegaly. Metabolism 2003, 52:181-185.
51. Ronchi C.L., Varca V., Giavoli C., et al. Long term evaluation of postoperative acromegalic patients in remission with previously and newly proposed criteria. J Clin Endocrinol Metab 2005, 90:1377-1382.
52. Nomikos P., Buchfelder M., Fahlbusch R. The outcome of surgery in 668 patients with acromegaly using current criteria of biochemical "cure". Eur J Endocrinol 2005, 152:379-387.
53. Colao A., Pjvonello R., Auriemma R.S. Predictors of tumor shrinkage after primary therapy with somatostatin analogs in acromegaly; a prospective study in 99 patients. J Clin Endocrinol 2006, 2112-2118.
54. Paisley A.N., Rowles S.V., Roberts M.E. Treatment of acromegaly improves quality of life, measured by AcroQol. Clin Endocrinol 2007, 67:358-362.
55. Kauppinen-Makelin R., Sane T., Sintomen H. Quality of life in treated patients with acromegaly. J Clin Endocrinol Metab 2006, 91:3891-3896.
56. Trepp R., Everts R., Stettler C. Assessment of quality of life in patients with uncontrolled vs controlled acromegaly using the acromegaly quality of life questionnaire (AcroQoL). Clin Endocrinol 2005, 63:103-110.
57. Holdaway I.M., Bolland M.J., Gamble G.D. A meta-analysis of the effect of lowering serum levels of GH and IGF-I on mortality in acromegaly. Eur J Endocrinol 2008, 159:89-95.
58. Swearingen B., Barker F.G., Katnezlson L., et al. Long-term mortality after transsphenoidal surgery and adjunctive therapy for acromegaly. J Clin Endocrinol Metab 1998, 83:3419-3426.
59. Beauregard C., Truong U., Hardy J., Serri O. Long-term outcome and mortality after transsphenoidal adenomectomy for acromegaly. Clin Endocrinol 2003, 58:86-91.
60. Biermasz N.R., Dekker F.W., Pereira A.M., et al. Determinants of survival in treated acromegaly in a single center: predictive value of serial insulin-like growth factor I measurements. J Clin Endocrinol Metab 2004, 89:2789-2796.
61. Trepp R., Stettler C., Zwahlen M., Sieler R., Diem P., Christ E.R. Treatment outcomes and mortality of 94 patients with acromegaly. Acta Neurochir 2003, 147:243-251.
62. Kauppinen-Makelin R., Sane T., Reunanen A., et al. A nationwide survey of mortality in acromegaly. J Clin Endocrinol Metab 2005, 90:4081-4086.
63. Bates A.S., Van't Hoff W., Jones J.W., Clayton R.N. An audit of outcome of treatment in acromegaly. Q J Med 1993, 86:293-299.
64. Orme S.M., McNally R.J., Cartwright R.A., Belchetz P.E. Mortality and cancer incidence in acromegaly: a restrospective cohort study. United Kingdom Acromegaly Study Group. J Clin Endocrinol Metab 1998, 83:2730-2734.
65. Arita K., Kurisu K., Tominaga A., et al. Mortality in 154 surgically treated patients with acromegaly-a 10year follow up survey. Endocr J 2003, 50:163-172.
66. Seth J., Ellis A., Al-Sadie R. Serum growth hormone measurements in clinical practice: an autid of performance from the UK National External Quality Assessment scheme. Horm Res 1999, 51:13-19.
67. Arafat A.M., Mohlig M., Weickert M.O., et al. Growth hormone response during oral glucose tolerance test: the impact of assay method on the estimation of reference values in patients with acromegaly and in healthy controls, and the role of gender, age and body mass index. J Clin Endocrinol Metab 2007, 93:1254-1262.
68. Krebs A., Wallaschofski H., Spilcke-Liss E., et al. Five commercially available insulin-like growth factor I (IGF-I) assays in comparison to the former Nichols Advantage IGF-I in a growth hormone treated population. Clin Chem Lab Med 2008, 1776-1783.
69. Bidlingmaier M., Freda P. Measurement of human growth hormone by immunoassays: current status, unsolved problems and clinical consequences. Growth Horm IGF Res 2010, 20:19-25.
70. Burns C., Risby P., Moore M., Rafferty B. The first international standard for insulin-like growth factor I (IGF-I) for immunoassay: preparation and calibration in an international collaborative study. Growth Horm IGF Res 2009, 457-462.
71. Frystyk J., Freda P., Clemmons D.R. The current status of IGF-I assays-a 2009 update. Growth Horm &IGF Res 2010, 20:8-18.
72. Morsky P., Tlikkainen U., Ruokonen A., Markkanen H. Problematic determination of serum growth hormone: experience from external quality assurance surveys 1998-2003. Scand J Clin Lab Investig 2005, 65:377-386.